Journal: Journal for Immunotherapy of Cancer

Article Title: CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

doi: 10.1136/jitc-2024-011066

Figure Lengend Snippet: CD40L enhances the expansion of melanoma TIL. Melanoma single-cell suspensions were cultured in standard TIL expansion media (control) or media supplemented with an agonist of CD40 (CD40L) for 3–4 weeks. ( A ) TIL expansion success rate (n=21 patients) using control or CD40L-supplemented media. *p≤0.05 (χ 2 ). ( B ) Cell counts of total viable cells, CD4 + and CD8 + T cells after 4 weeks of expansion. Individual values are plotted with lines connecting the paired samples, corresponding to individual patients. The dashed line represents one patient with no expansion in the control condition. This patient was not considered for the statistical analysis (n=14). *p≤0.05, **p≤0.01, ***p≤0.001 (Wilcoxon signed-rank test). ( C ) Differentiation phenotype analyzed by flow cytometry in pre-REP TIL (Effector Memory: CCR7 − CD45RA − ; Central Memory: CCR7 + CD45RA − ; Naive: CCR7 + CD45RA + ; CD45 + Effector Memory: CCR7 − CD45RA + ). Individual values are plotted with lines connecting the paired samples, corresponding to individual patients. The dashed line represents one patient with no expansion in the control condition. This patient was not considered for the statistical analyses (n=14). *p≤0.05 (Wilcoxon signed-rank test). Scatter plot of a representative example is shown in the right panel. ( D ) Expression of CD39 and CD69 in TIL (gated on lymphoid, single, live, CD3 + cells) after 4 weeks of ex vivo expansion. Individual values are plotted with lines connecting the paired samples. The dashed lines represent patients with no expansion in the Control condition. For two of the patients a control sample expanded from fragments was used for comparison (black line). In the third patient, a value of zero was attributed to the control condition with no expansion (gray line). Those patients were not considered for the statistical analyses (n=11). *p≤0.05 (Wilcoxon signed-rank test). One outlier removed based on Grubb’s test. ( E ) Analysis of reactivity of melanoma TIL. Expanded T-cells were cultured with autologous tumor single-cell suspensions for 24 hours, at an E:T ratio of 1:1. Tumor reactivity was assessed by IFN-γ levels in the supernatant. Each graph represents an individual patient (n=4). TILs were expanded from tumor fragments (40355, 40348 and 40372) or tumor digest (40298). ‘Pool’ indicates TIL co-cultures generated from more than one fragment pooled together. ‘F’ indicates data from a single fragment. The black bar represents TIL co-cultured with autologous tumor cells (Digest). The gray bar represents TIL co-cultured with autologous tumor cells (Digest) preincubated with anti-HLA class I blocking antibody (W6/32). Reactivity was defined by secretion of >50 pg/mL of IFN-γ, inhibited by at least 20% when the HLA-I antibody was used. TILs, tumor-infiltrating lymphocytes.

Article Snippet: For certain analyses, TILs were expanded from lung tumor fragments, approximately 1–2 mm 2 , in 24-well plates under two different conditions, 6000 IU/mL IL-2 alone (Proleukin), or in 6000 IU/mL IL-2 plus 1000 ng/mL human recombinant CD40L (Miltenyi Biotec, 130-098-776) for 3–4 weeks.

Techniques: Cell Culture, Control, Flow Cytometry, Expressing, Ex Vivo, Comparison, Generated, Blocking Assay

Journal: Journal for Immunotherapy of Cancer

Article Title: CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

doi: 10.1136/jitc-2024-011066

Figure Lengend Snippet: Melanoma infiltrating B-cells upregulate costimulatory ligands in response to CD40L. ( A–D ) Percentage of CD45 + cells ( A ), T-cells (CD45 + CD3 + CD19 − ) ( B ), B-cells (CD45 + CD3 − CD19 + ) ( C ), and non-B/non-T cells (CD45 + CD3 − CD19 − ) ( D ) present in melanoma single-cell suspensions, grouped based on their ability to yield TIL expansion. Individual values corresponding to independent patients are plotted with mean±SEM (n=20). *p≤0.05 (Mann-Whitney U test). ( E ) Relative abundance of different B-cell subsets (Switched memory: CD27 + IgD − ; Unswitched memory: CD27 + IgD + ; Naive: CD27 − IgD + ; Double-Negative: CD27 − IgD − ) present in melanoma tumor digests based on their ability to yield TIL expansion. Individual values are plotted with mean±SEM (n=24). *p≤0.05, ***p≤0.001 (Mann-Whitney U test). ( F ) Flow cytometry analysis of CD40 expression in myeloid cells (CD45 + CD3 − CD19 − HLA-DR + ) and B-cells (CD45 + CD3 − CD19 + ) present in melanoma tumor digests. The individual values are plotted with lines connecting the paired samples corresponding to the same patient (n=11). ***p≤0.001 (paired Wilcoxon signed-rank test). A representative histogram of CD40 expression is also shown. ( G, H ) Flow cytometry analysis of HLA-DR, DQ, DP expression and percentage of CD80/CD86 double positive cells within myeloid cells (CD45 + CD3 − CD19 − HLA-DR + ) and B-cells (CD45 + CD3 − CD19 + ) present in melanoma tumor digests. Tumor digests were cultured for 48 hours in standard TIL expansion media (control) or supplemented with a CD40 agonist (CD40L). Individual values corresponding to independent patients are plotted with mean±SEM (n=10). ***p≤0.001, ****p≤0.0001 (two-way ANOVA and Tukey’s multiple comparison test). ANOVA, analysis of variance.

Article Snippet: For certain analyses, TILs were expanded from lung tumor fragments, approximately 1–2 mm 2 , in 24-well plates under two different conditions, 6000 IU/mL IL-2 alone (Proleukin), or in 6000 IU/mL IL-2 plus 1000 ng/mL human recombinant CD40L (Miltenyi Biotec, 130-098-776) for 3–4 weeks.

Techniques: MANN-WHITNEY, Flow Cytometry, Expressing, Cell Culture, Control, Comparison

Journal: Journal for Immunotherapy of Cancer

Article Title: CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

doi: 10.1136/jitc-2024-011066

Figure Lengend Snippet: Immune cell composition of melanoma tumors and response to CD40L. Melanoma digests were cultured in standard TIL expansion media (control) or supplemented with an agonist of CD40 (CD40L) for 48 hours (n=14 samples, 7 patients) and analyzed by single-cell RNA sequencing. ( A ) UMAP projection of different cell populations identified in the tumor digests. ( B ) UMAP projection of the tumor digests based on culture conditions (CD40L vs control). ( C ) UMAP projection of B-cells, showing expression of IgA, IgD, IgE, IgG1, IgG2, IgG3, IgG4 and IgM antibody/BCR isotypes. ( D ) UMAP projection of B-cells showing subclusters identified by the Seurat algorithm. Clusters corresponding to CD40L-treated samples are indicated with the red square. ( E ) Cross-referencing of B-cell clusters with previously described gene sets corresponding to naive, memory, germinal center (GC) and plasma cells. TIL, tumor-infiltrating lymphocyte.

Article Snippet: For certain analyses, TILs were expanded from lung tumor fragments, approximately 1–2 mm 2 , in 24-well plates under two different conditions, 6000 IU/mL IL-2 alone (Proleukin), or in 6000 IU/mL IL-2 plus 1000 ng/mL human recombinant CD40L (Miltenyi Biotec, 130-098-776) for 3–4 weeks.

Techniques: Cell Culture, Control, RNA Sequencing, Expressing, Clinical Proteomics

Journal: Journal for Immunotherapy of Cancer

Article Title: CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

doi: 10.1136/jitc-2024-011066

Figure Lengend Snippet: CD40L induces gene expression changes in melanoma infiltrating B-cells. Melanoma digests were cultured in standard TIL (control) or CD40L-supplemented media for 48 hours (n=14 samples, 7 patients). ( A ) Volcano plot displaying differentially expressed genes in CD40L-treated versus control B-cells assessed by scRNA-seq (Log2FC=0.95; p≤0.05). Upregulated genes are shown in red. Downregulated genes are shown in blue. ( B–D ) UMAP projections of the B-cell compartment, showing expression of differentially expressed genes CD86, CCL22, and FcRL4. ( E ) Flow cytometry analysis of CCL22 expression in melanoma infiltrating B-cells. Individual values are plotted with lines connecting the paired samples corresponding to individual patients (n=22). ****p≤0.0001 (Wilcoxon signed-rank test). Flow cytometry scatter plot of a representative example shown in the right panel. ( F ) Flow cytometry analysis of FcRL4 expression in melanoma infiltrating B-cells. Individual values are plotted with lines connecting the paired samples (n=22). ***p≤0.001 (paired Wilcoxon signed-rank test). Representative example shown in the right panel. ( G ) UMAP projection of B-cells showing expression of CD58. ( H ) Flow cytometry analysis of CD58 expression in B-cells cultured in standard (control) or CD40L-supplemented media for 48 hours. Individual values are plotted with lines connecting the paired samples corresponding to individual patients (n=22). ****p≤0.0001 (paired Wilcoxon signed-rank test). ( I ) Percentage of CD58 positive B-cells in samples grouped based on their ability to yield TIL expansion (successful expansion, n=13; unsuccessful expansion, n=9). ns=not statistically significant, ***p≤0.01 (paired Wilcoxon signed-rank test). TIL, tumor-infiltrating lymphocyte.

Article Snippet: For certain analyses, TILs were expanded from lung tumor fragments, approximately 1–2 mm 2 , in 24-well plates under two different conditions, 6000 IU/mL IL-2 alone (Proleukin), or in 6000 IU/mL IL-2 plus 1000 ng/mL human recombinant CD40L (Miltenyi Biotec, 130-098-776) for 3–4 weeks.

Techniques: Gene Expression, Cell Culture, Control, Expressing, Flow Cytometry

Journal: Journal for Immunotherapy of Cancer

Article Title: CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

doi: 10.1136/jitc-2024-011066

Figure Lengend Snippet: CD40L enhances the expansion of NSCLC TIL and increases the frequency of neoantigen reactive T-cells. ( A–E ) Lung tumor fragments were cultured in standard TIL expansion media (control) or supplemented with an agonist of CD40 (CD40L) for 3–4 weeks. ( A ) TIL expansion success rate of individual tumor fragments, derived from 12 independent patients. *p≤0.05 (χ 2 ). ( B ) Cell counts of total viable cells after 4 weeks of ex vivo expansion. Individual values are plotted with lines connecting the paired samples, corresponding to individual patients (n=12). **p<=0.01 (Mann-Whitney U test). ( C ) Cell counts of total viable cells per fragment (control: n=87; CD40L: n=92). ****p≤0.0001 (Mann-Whitney U test). ( D ) Number of TIL cultures arising from individual tumor fragments, over time (control: n=87; CD40L: n=92). ****p≤0.0001 (non-linear fit test). ( E ) Violin plots representing the percentage of CD39 − CD69 − T-cells after 4 weeks of ex vivo expansion, as determined by flow cytometry (control: n=87; CD40L: n=92). **p≤0.01 (paired t-test). ( F ) Analysis of TIL reactivity against autologous tumor. NSCLC TILs were cultured with autologous tumor single-cell suspensions for 24 hours at an E:T ratio of 1:1. Reactivity was assessed by IFN-γ levels in the supernatant, quantified using the ELLA platform. Each graph represents an individual patient (n=5). TILs were expanded from fragments (samples 195226, 197743 and 186545) or tumor digest (170592 and 190664). ‘Pool’ indicates TIL cultures generated from more than one fragment pooled together. ‘F’ denotes TIL cultures derived from an individual fragment. Black bars represent TIL co-cultured with autologous tumor cells (Digest). Gray bar represents TIL co-cultured with autologous tumor cells (Digest) preincubated with anti-HLA class I blocking antibody (W6/32). ( G ) Lung tumor digests were cultured in standard TIL expansion media (control) or supplemented with an agonist of CD40 (CD40L) for 3–4 weeks, followed by a Rapid Expansion Protocol (REP) culture. The percentage of antigen-specific T-cell receptor clonotypes within post-REP TIL are represented for three patient samples. The neoantigen related to each clonotype is also described in the figure. NSCLC, non-small cell lung cancer; TIL, tumor-infiltrating lymphocyte.

Article Snippet: For certain analyses, TILs were expanded from lung tumor fragments, approximately 1–2 mm 2 , in 24-well plates under two different conditions, 6000 IU/mL IL-2 alone (Proleukin), or in 6000 IU/mL IL-2 plus 1000 ng/mL human recombinant CD40L (Miltenyi Biotec, 130-098-776) for 3–4 weeks.

Techniques: Cell Culture, Control, Derivative Assay, Ex Vivo, MANN-WHITNEY, Flow Cytometry, Generated, Blocking Assay